ArticlePigment cell & melanoma research2014
High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients.
Article in Pigment cell & melanoma research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center.Cancers · 2023Article
- Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma.Scientific reports · 2022Article
- Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification.Acta dermato-venereologica · 2021Article
- Xeroderma Pigmentosum: A Model for Human Premature Aging.The Journal of investigative dermatology · 2021Review
- Imaging of pediatric cutaneous melanoma.Pediatric radiology · 2019Review
- cAMP-mediated regulation of melanocyte genomic instability: A melanoma-preventive strategy.Advances in protein chemistry and structural biology · 2019Review
- Review
- Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.International journal of molecular sciences · 2017Review
- ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.Cell reports · 2017Article
- Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis.Photochemistry and photobiology · 2017Review
- Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders.British journal of clinical pharmacology · 2016Review
- High intensity focused ultrasound inhibits melanoma cell migration and metastasis through attenuating microRNA-21-mediated PTEN suppression.Oncotarget · 2016Article
- Xeroderma Pigmentosum.Head and neck pathology · 2016Review
- Phytochemicals for the Management of Melanoma.Mini reviews in medicinal chemistry · 2016Review
- Conceptual approach to early melanoma detection: models, tools, issues and challenges.Melanoma management · 2015Review
- Detection of UV-induced cyclobutane pyrimidine dimers by near-infrared spectroscopy and aquaphotomics.Scientific reports · 2015Article
- Forty years of research on xeroderma pigmentosum at the US National Institutes of Health.Photochemistry and photobiologyReview
- UV signature mutations.Photochemistry and photobiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
We examined nevi and melanomas in 10 xeroderma pigmentosum (XP) patients with defective DNA repair. The lesions had a lentiginous appearance with markedly increased numbers of melanocytes. Using laser capture microdissection, we performed DNA sequencing of 18 benign and atypical nevi and 75 melanomas (melanoma in situ and invasive melanomas). The nevi had a similar high frequency of PTEN mutations as melanomas [61% (11/18) versus 53% (39/73)]. Both had a very high proportion of UV-type mutations (occurring at adjacent pyrimidines) [91% (10/11) versus 92% (36/39)]. In contrast to melanomas in the general population, the frequency of BRAF mutations (11%, 7/61), NRAS mutations (21%, 13/62), and KIT mutations (21%, 6/28) in XP melanomas was lower than for PTEN. Phospho-S6 immunostaining indicated activation of the mTOR pathway in the atypical nevi and melanomas. Thus, the clinical and histological appearances and the molecular pathology of these UV-related XP nevi and melanomas were different from nevi and melanomas in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.